How Does NRDL Pricing Work for Foreign Drugs in China?

1. Understanding the NRDL Framework

The National Reimbursement Drug List (NRDL) is China’s primary mechanism for determining which drugs are covered by the national basic medical insurance system, which covers over 95% of China’s 1.4 billion population. For foreign pharmaceutical companies, NRDL listing is the single most important factor determining market access and commercial success in China.

The NRDL is managed by the National Healthcare Security Administration (NHSA), established in 2018 to consolidate drug pricing, procurement, and reimbursement functions previously scattered across multiple agencies. The NHSA conducts annual NRDL negotiations, typically announced in the fourth quarter, with updated lists taking effect the following calendar year.

The NRDL is divided into several categories. Western medicines constitute the largest category, followed by traditional Chinese medicines (TCMs), with separate sections for pediatric drugs and rare disease drugs under the updated 2024 framework. As of the 2025 NRDL (effective January 2026), the list covers approximately 3,200 drugs, including over 200 imported drugs from foreign manufacturers.

2. The NRDL Entry Pathways

Foreign drugs can enter the NRDL through two main pathways:

2.1 Conventional Listing (Catalog A)

Category A drugs are essential medicines with established clinical use and multiple market entrants. These drugs are typically generics or well-established brands where the NHSA sets a uniform reimbursement price based on market competition and pharmacoeconomic analysis. Foreign drugs in Category A are reimbursed at 100% of the NHSA-determined price, with no patient co-payment beyond standard insurance deductibles.

For most foreign innovative drugs, however, the Category A pathway is not the primary route. Category A prices are generally low (often at or near generic levels), and foreign innovators typically prefer to negotiate for Category B status, which offers better pricing through negotiation.

2.2 Negotiated Listing (Catalog B)

Category B is the primary pathway for innovative foreign drugs. Under this pathway, the NHSA conducts annual price negotiations with drug manufacturers. Key characteristics include:

• Mandatory negotiation: The NHSA selects drugs for negotiation annually based on clinical need, innovation level, and budget impact
• Confidential pricing: Negotiated prices are officially kept confidential (though often leaked), with the NHSA and manufacturer bound by non-disclosure agreements
• Patient co-payment: Category B drugs require a patient co-payment (typically 10-30% of the negotiated price, varying by province)
• Two-year validity: Negotiated prices are valid for two years, after which re-negotiation is required

3. The NRDL Price Negotiation Process

The annual NRDL negotiation process follows a structured timeline and methodology:

3.1 Selection and Application (February-April)

The NHSA publishes annual selection criteria and invites drug manufacturers to submit applications for NRDL inclusion. Drugs eligible for negotiation include:

• New drugs approved by the NMPA within the past 5 years
• Drugs with new indications approved since their last NRDL negotiation
• Drugs in therapeutic areas with significant unmet medical need
• Pediatric drugs, rare disease drugs, and innovative drugs with breakthrough therapy designation

Foreign manufacturers submit a dossier including clinical evidence, cost-effectiveness data, budget impact analysis, and pricing information from other markets. The dossier format follows NHSA guidelines that have been progressively aligned with international HTA (Health Technology Assessment) standards.

3.2 Expert Evaluation (May-August)

The NHSA convenes expert panels to evaluate each drug candidate through several dimensions:

• Clinical value assessment: Efficacy, safety, and clinical benefit compared to existing treatments, with emphasis on head-to-head trial data
• Pharmacoeconomic evaluation: Cost-effectiveness analysis including incremental cost-effectiveness ratios (ICERs) compared to standard of care, typically expressed in cost per quality-adjusted life year (QALY) gained
• Budget impact analysis: Projected total cost to the insurance system based on expected patient numbers, duration of therapy, and market penetration rates
• Innovation premium: Additional consideration for first-in-class drugs, breakthrough therapies, and drugs addressing previously unmet needs

3.3 Face-to-Face Negotiation (September-October)

The most intense phase of the process involves direct negotiation between NHSA officials and manufacturer representatives. Key characteristics of the negotiation include:

• Single-round primary negotiation: The NHSA presents its initial price offer based on expert evaluations. Manufacturers typically have one opportunity to counter-propose
• Price reduction expectations: The NHSA typically seeks price reductions of 40-70% from the drug’s current market price (for drugs already on the market) or from the manufacturer’s initial asking price
• Confidential negotiation outcomes: The agreed price is recorded in a confidential appendix to the NRDL
• Take-it-or-leave-it aspect: If the manufacturer’s counter-proposal exceeds the NHSA’s “maximum acceptable price” (the so-called “bottom line”), the drug is excluded from the NRDL for that year

4. The Impact of NRDL Pricing on Foreign Drug Companies

4.1 Volume vs. Margin Trade-off

The fundamental strategic question for foreign pharma companies is whether NRDL inclusion at significantly reduced prices is commercially viable. The experience of companies that have chosen to enter the NRDL demonstrates a consistent pattern:

• Immediate revenue drop: In the first year after NRDL inclusion, drug revenues typically decline by 30-50% due to price reductions
• Volume growth: Over 2-3 years, patient volume typically increases by 100-300% as hospital access improves and insurance coverage drives demand
• Revenue recovery: Most drugs reach or exceed pre-NRDL revenue levels within 3-4 years, driven by expanded patient access
• Long-term sustainability: NRDL-listed drugs benefit from stable reimbursement and predictable demand, supporting long-term market presence

However, this pattern varies significantly by therapeutic area. Oncology drugs with large addressable patient populations tend to recover more quickly, while specialty drugs for rare diseases may never achieve the volume needed to offset price reductions.

4.2 Strategic Approaches to NRDL Negotiation

Foreign companies employ several strategies to optimize NRDL outcomes:

• Launch pricing strategy: Companies increasingly set China launch prices that anticipate a 40-60% NRDL discount, avoiding the need for steep reductions from an initially high price
• Value dossier preparation: Investing in China-specific health economics data, including local cost-effectiveness studies and real-world evidence from Chinese populations
• Subgroup targeting: Focusing NRDL applications on well-defined patient subpopulations where the drug offers the strongest clinical and cost-effectiveness profile
• Sequential indication expansion: Negotiating NRDL entry for one indication first, then adding additional indications in subsequent rounds with supplementary clinical data
• Patient assistance programs (PAPs): Offering supplementary PAPs to reduce patient out-of-pocket costs beyond insurance coverage, making the drug more affordable while maintaining the NRDL price

5. The Provincial Implementation Layer

NRDL pricing is set at the national level, but implementation varies significantly across China’s 31 provinces:

5.1 Provincial Tender and Procurement

After NRDL inclusion, each province conducts its own procurement process to determine which hospitals can prescribe the drug and at what distribution margins. Key provincial variations include:

• Hospital quota management: Some provinces impose prescribing quotas or usage caps on high-cost NRDL drugs
• “Double channel” policy: Allows patients to purchase NRDL drugs at designated retail pharmacies rather than hospital pharmacies, expanding access but requiring separate pharmacy contracting
• Local tender conditions: Provincial tender documents may require additional price concessions beyond the NRDL price for distribution and hospital access

5.2 Volume-Based Procurement (VBP) Interaction

For drugs that face generic competition, the national Volume-Based Procurement (VBP) program presents a separate pricing mechanism that interacts with NRDL pricing. Key considerations for foreign companies include:

• Branded drugs that lose patent protection may face VBP tenders with price reductions of 50-90%
• Foreign companies typically face a choice between participating in VBP at deep discounts or pursuing a “non-VBP” strategy focusing on the private-pay and out-of-pocket market
• NRDL-listed drugs that go generic are typically moved from Category B to Category A with substantially reduced prices set by VBP outcomes

6. 2026 NRDL Updates and Trends

The 2026 NRDL cycle (announced late 2025, taking effect January 2026) introduced several important changes for foreign pharmaceutical companies:

• Expanded rare disease coverage: A dedicated rare disease drug negotiation process with modified pharmacoeconomic criteria recognizing the higher ICER thresholds acceptable for orphan drugs
• Pediatric drug incentives: Priority review for pediatric drug NRDL applications, with evaluation criteria weighted toward age-appropriate formulations and pediatric-specific clinical data
• Cell and gene therapy evaluation: A new evaluation framework for one-time curative therapies, using annualized cost models rather than per-treatment pricing
• Real-world evidence acceptance: Formal incorporation of real-world evidence (RWE) into the pharmacoeconomic evaluation, potentially reducing the need for expensive local RCT data
• Digital therapeutics coverage: A pilot framework for evaluating digital therapeutics (software-based treatments) for NRDL inclusion, opening a new category beyond traditional pharmaceuticals

7. Alternatives to NRDL Inclusion

Some foreign pharmaceutical companies choose not to participate in the NRDL, pursuing alternative market access strategies:

7.1 Private Insurance and Out-of-Pocket Market

China’s private health insurance market has grown rapidly, with premium income exceeding $100 billion annually. Some foreign drugs target the private insurance channel, where pricing is unregulated and patients have higher willingness to pay. However, this strategy limits the addressable patient population to approximately 5-10% of the total market.

7.2 Commercial Health Insurance Partnerships

Foreign companies increasingly partner with Chinese commercial insurers (Ping An, Taikang, China Life) and online health platforms to create supplemental insurance products covering non-NRDL drugs. These partnerships can provide partial market access without NRDL negotiation.